Sangoro, Onyango P.
Gavana, Tegemeo
Finda, Marceline
Mponzi, Winfrida
Hape, Emmanuel
Limwagu, Alex
Govella, Nicodem J.
Chaki, Prosper
Okumu, Fredros O.
Funding for this research was provided by:
Grand Challenges Canada (S5-0442-01)
Article History
Received: 21 January 2020
Accepted: 30 March 2020
First Online: 8 April 2020
Ethics approval and consent to participate
: Ethical approval for the study was obtained from Ifakara Health Institute Institutional Review Board (IHI-IRB)—IHI/IRN/No; 18-2014 and the Tanzanian National Institute of Medical Research (NIMR/HQ/R.8a/VOL IX/2199). All volunteers were asked for verbal as well as written informed consent to participate in the study after study objectives had been explained to them and all their questions answered. Malaria tests were provided to all volunteers before, during and after the study, with the intention that only malaria-free individuals would be allowed to participate in the experiments. All volunteers involved in HLCs in the field were provided with prophylaxis (250 mg Mefloquine taken orally) once every week to prevent malaria infections during the course of the experiments. In addition, treatment (Coartem<sup>®</sup>, 80 mg artemether and 480 mg lumefantrine for 3 days) was made available in case any of the participants became ill.The initial experiments reported in this study conducted from January 2014 to October 2015, were conducted using human landing catches (HLC). The subsequent experiments conducted from October 2016 to September 2018 employed the use of the mosquito electrocuting trap (MET) after Ifakara health institute banned the use of HLC in experiments.
: This manuscript has been approved for publication by National Institute of Medical Research, United Republic of Tanzania, Reference number: NIMR/HQ/P.12 VOL XXIX/25.
: The authors declare no competing interests.